Oral octreotide gets green light from European body

The European Medicines Agency’s Committee for Orphan Medicinal Products has adopted a positive opinion for “orphan designation” for the use of the oral octreotide Mycapssa in the treatment of carcinoid syndrome associated with neuroendocrine tumors. Mycapssa, already approved in the US and Europe for use by acromegaly patients, is a product of Amryt Pharma. “Orphan designation” is a status reserved for drugs used in treating rare diseases. Read the press release.